Cost Curve News - News - https://www.costcurvenews.com/blog/page/9/

Lilly Says Lists Prices Rose 3.8% Last Year, Though the Net Prices Tell a More Fascinating Story

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

APEX Special Edition: All Things IRA

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

APEX Special Edition: All Things Price and Oncology

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

Pfizer’s Pricing Transparency Disclosures Are Out; The Company’s Net Prices Fell 2% Last Year

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

The Wait for 340B Rebate Model Guidance from the Government Just Got Longer

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

Reading on 340B … While Waiting on 340B

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

The Government Could Upend 340B Next Week. Here Are Three Ways That Could Go Down

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

Companies Have a Unique Opportunity to Seize the MFN Narrative. Here Are Seven Ways to Do That

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

A Must-Read Assessment of 340B Legislation Encourages Policymakers to Think Hard About ‘Tradeoffs’

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

APEX | The Current State of Play on MFN: Skepticism on Administrative Execution, Attention Around Congressional Action

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Lilly Says Lists Prices Rose 3.8% Last Year, Though the Net Prices Tell a More Fascinating Story

APEX Special Edition: All Things IRA

APEX Special Edition: All Things Price and Oncology

Pfizer’s Pricing Transparency Disclosures Are Out; The Company’s Net Prices Fell 2% Last Year

The Wait for 340B Rebate Model Guidance from the Government Just Got Longer

Reading on 340B … While Waiting on 340B

The Government Could Upend 340B Next Week. Here Are Three Ways That Could Go Down

Companies Have a Unique Opportunity to Seize the MFN Narrative. Here Are Seven Ways to Do That

A Must-Read Assessment of 340B Legislation Encourages Policymakers to Think Hard About ‘Tradeoffs’

APEX | The Current State of Play on MFN: Skepticism on Administrative Execution, Attention Around Congressional Action

Latest Posts

Putting All of the Pharm-to-Table Resources in One Place

With the Pfizer/TrumpRx Announcement in the Rearview Mirror, Here Are Some Questions That Remain

The Four Elements of the Pfizer/Trump Deal to Keep an Eye On

Trump Makes a Deal with Pfizer on Medicaid and Announces a Direct-to-Patient Website

PhRMA Unveils a Three-Point Plan to Address Trump Concerns About Drug Prices and Manufacturing

Popular

Putting All of the Pharm-to-Table Resources in One Place

With the Pfizer/TrumpRx Announcement in the Rearview Mirror, Here Are Some Questions That Remain

The Four Elements of the Pfizer/Trump Deal to Keep an Eye On

Trump Makes a Deal with Pfizer on Medicaid and Announces a Direct-to-Patient Website

PhRMA Unveils a Three-Point Plan to Address Trump Concerns About Drug Prices and Manufacturing

Tariffs and MFN Dominate the Headlines, But Details Remain Scant

Latest News

Putting All of the Pharm-to-Table Resources in One Place

With the Pfizer/TrumpRx Announcement in the Rearview Mirror, Here Are Some Questions That Remain

Subcribe To Newsletter